How Joe Rogan’s Text Led to Trump’s Psychedelic Healthcare Order

On April 18, 2026, President Donald Trump, Secretary of Health and Human Services Robert F. Kennedy, and podcaster Joe Rogan gathered in the Oval Office. The meeting followed a pivotal moment: Rogan’s text to Trump had just set in motion a sweeping executive order on psychedelic drug research and therapy.

Rogan’s Text Sparked a White House Response

Rogan, a longtime advocate for psychedelic therapy, revealed he had sent Trump a text outlining the potential of substances like psilocybin and MDMA in treating depression and PTSD. The president’s response was immediate: “Sounds great. Do you want FDA approval? Let’s do it.”

Mehmet Oz, the celebrity doctor overseeing Medicare and Medicaid, confirmed to reporters that Rogan’s message triggered a week of rapid internal deliberations, culminating in the executive order. Trump later praised the swift action, saying,

“I said, ‘Bobby, let’s just do it and get Oz involved and it’s going to get done so quickly.’ And you guys did a great job.”

What the Executive Order Does

The order directs the Department of Health and Human Services to increase funding for psychedelic research and urges the Drug Enforcement Agency to update guidelines to facilitate academic and therapeutic use. These steps align with growing evidence that psychedelics may offer breakthrough treatments for mental health conditions.

However, the order also includes a controversial provision: it instructs the FDA to grant psychedelic manufacturers priority review vouchers, which expedite drug approvals. Critics argue this undermines the FDA’s scientific rigor and may reflect political concessions rather than medical necessity.

Concerns Over Political Influence

Rachel Sachs, a Washington University law professor specializing in drug regulation, expressed alarm:

“The optics of the situation are quite concerning. It appears that the president is directing the FDA, at the very least, to prioritize certain products based on political considerations rather than scientific evidence.”

Peter Lurie, president of the Center for Science in the Public Interest, offered a more measured view:

“It’s well within the remit of any administration to decide that research in a given area is a priority for them, and to make it easier for researchers to do that work.”

Potential Profiteering and Industry Ties

Observers also question whether the order benefits companies with ties to Trump allies. Notably, Peter Thiel, a prominent Trump supporter, has invested in psychedelic therapy firms that could profit from expedited approvals. The White House has not addressed these concerns.

The executive order marks a dramatic shift in U.S. drug policy, but its rapid implementation and political underpinnings have left many questioning the balance between innovation and regulatory integrity.